Claims for Patent: 9,205,079

Summary for Patent: 9,205,079

Title:	Hepatitis B antiviral agents
Abstract:	Provided herein are compounds useful for the treatment of HBV infection in man.
Inventor(s):	Hartman; George D. (Lansdale, PA)
Assignee:	Novira Therapeutics, Inc. (Doylestown, PA)
Application Number:	14/642,393
Patent Claims:	1. A method of treating an HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound of Formula I: ##STR00120## or a pharmaceutically acceptable salt thereof, wherein: Ring A is selected from: ##STR00121## wherein: G is N, and Q is CH.sub.2 or NR.sup.3, or G is NR.sup.3, and Q is CH or N, or G is CH, and Q is NR.sup.3, or G is CH.sub.2, and Q is N; and ---- represents a single or double bond; R.sup.1 in each occurrence is independently selected from halo, --CN, C.sub.1-6alkyl, --OC.sub.1-6alkyl, and --NO.sub.2, wherein the C.sub.1-6alkyl is optionally substituted with one to three halo; R.sup.2 in each occurrence is independently selected from hydrogen, halo, and C.sub.1-6alkyl; R.sup.3 is selected from H and C.sub.1-6alkyl; R.sup.4 in each occurrence is independently selected from halo, C.sub.1-6alkyl, monocyclic 5 to 7-membered carbocyclyl, monocyclic 5 to 7-membered heterocyclyl, --OR.sup.4a, --SR.sup.4a, and --N(R.sup.4a).sub.2 wherein the C.sub.1-6alkyl, monocyclic 5 to 7-membered carbocyclyl, and monocyclic 5 to 7-membered heterocyclyl are optionally substituted with one or more R.sup.40; R.sup.4a in each occurrence is independently selected from H, C.sub.1-6alkyl, monocyclic 5 to 7-membered carbocyclyl, and monocyclic 5 to 7-membered heterocyclyl, wherein said C.sub.1-6alkyl, monocyclic 5 to 7-membered carbocyclyl, and monocyclic 5 to 7-membered heterocyclyl, are optionally and independently substituted with one or more R.sup.40; R.sup.5 is selected from H and C.sub.1-6alkyl; R.sup.40 in each occurrence is independently selected from halo, --CN, C.sub.1-6 alkyl, monocyclic 5 to 7-membered carbocyclyl, monocyclic 5 to 7-membered heterocyclyl, --OR.sup.40a, --SR.sup.40a, --N(R.sup.40a).sub.2, --NO.sub.2, --C(O)R.sup.40b, and --C(O).sub.2R.sup.40a; R.sup.40a in each occurrence is independently selected from H, C.sub.1-6alkyl, monocyclic 5 to 7-membered carbocyclyl, and monocyclic 5 to 7-membered heterocyclyl; R.sup.40b in each occurrence is independently selected from C.sub.1-6alkyl, monocyclic 5 to 7-membered carbocyclyl, and monocyclic 5 to 7-membered heterocyclyl; w is 0, 1, 2, or 3; x is 0 or 1; and y is 0, 1, or 2. 2. The method of claim 1, further comprising administering to the individual at least one additional therapeutic agent selected from the group consisting of a HBV polymerase inhibitor, interferon, pegylated interferon, viral entry inhibitor, viral maturation inhibitor, capsid assembly modulator, reverse transcriptase inhibitor, a TLR-agonist, AT-61 ((E)-N-(1-chloro-3-oxo-1-phenyl-3-(piperidin-1-yl)prop-1-en-2-yl)benzamid- e), and AT-130 ((E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-y- l)-4-nitrobenzamide), and a combination thereof. 3. The method of claim 2, wherein the pegylated interferon is pegylated interferon alpha (IFN-.alpha.), pegylated interferon lambda (IFN-.lamda.), or pegylated interferon gamma (IFN-.gamma.). 4. The method of claim 2, wherein the reverse transcriptase inhibitor is at least one of Zidovudine, Didanosine, Zalcitabine, ddA, Stavudine, Lamivudine, Abacavir, Emtricitabine, Entecavir, Apricitabine, Atevirapine, ribavirin, acyclovir, famciclovir, valacyclovir, ganciclovir, valganciclovir, Tenofovir, Adefovir, cidofovir, Efavirenz, Nevirapine, Delavirdine, or Etravirine. 5. The method of claim 2, wherein the compound and the at least one additional therapeutic agent are co-formulated. 6. The method of claim 2, wherein the compound and the at least one additional therapeutic agent are co-administered. 7. The method of claim 2, wherein administering the compound allows for administering the at least one additional therapeutic agent at a lower dose or frequency as compared to the administering of the at least one additional therapeutic agent alone that is required to achieve similar results in prophylactically treating an HBV infection in an individual in need thereof. 8. The method of claim 2, wherein before administering the therapeutically effective amount of the compound of Formula I, the individual is known to be refractory to a compound selected from the group consisting of a HBV polymerase inhibitor, interferon, pegylated interferon, viral entry inhibitor, viral maturation inhibitor, capsid assembly modulator, AT-61 ((E)-N-(1-chloro-3-oxo-1-phenyl-3-(piperidin-1-yl)prop-1-en-2-yl)benzamid- e), and AT-130 ((E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-y- l)-4-nitrobenzamide), and combination thereof. 9. The method of claim 2, wherein the administering of the compound reduces viral load in the individual to a greater extent compared to the administering of a compound selected from the group consisting of a HBV polymerase inhibitor, interferon, pegylated interferon, viral entry inhibitor, viral maturation inhibitor, capsid assembly modulator, AT-61 ((E)-N-(1-chloro-3-oxo-1-phenyl-3-(piperidin-1-yl)prop-1-en-2-yl)benzamid- e), and AT-130 ((E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-y- l)-4-nitrobenzamide), and combination thereof. 10. The method of claim 2, wherein the administering of the compound causes a lower incidence of viral mutation and/or viral resistance than the administering of a compound selected from the group consisting of a HBV polymerase inhibitor, interferon, pegylated interferon, viral entry inhibitor, viral maturation inhibitor, capsid assembly modulator, AT-61 ((E)-N-(1-chloro-3-oxo-1-phenyl-3-(piperidin-1-yl)prop-1-en-2-yl)benzamid- e), and AT-130 ((E)-N-(1-bromo-1-(2-methoxyphenyl)-3-oxo-3-(piperidin-1-yl)prop-1-en-2-y- l)-4-nitrobenzamide), and combination thereof. 11. The method of claim 3, wherein the pegylated interferon alpha is PEGASYS. 12. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: ##STR00122## or a pharmaceutically acceptable salt thereof. 13. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: ##STR00123## or a pharmaceutically acceptable salt thereof. 14. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: ##STR00124## or a pharmaceutically acceptable salt thereof. 15. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: ##STR00125## or a pharmaceutically acceptable salt thereof. 16. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: ##STR00126## or a pharmaceutically acceptable salt thereof. 17. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: ##STR00127## or a pharmaceutically acceptable salt thereof. 18. The method of claim 1, wherein the compound of Formula I is selected from the group consisting of: ##STR00128## or a pharmaceutically acceptable salt thereof.

Details for Patent 9,205,079

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Zr Pharma& Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	10/16/2002		2033-03-12
Zr Pharma& Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	01/07/2004		2033-03-12
Zr Pharma& Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	09/29/2011		2033-03-12
Hoffmann-la Roche Inc.	PEGASYS COPEGUS COMBINATION PACK	peginterferon alfa-2a and ribavirin		125083	06/04/2004		2033-03-12